Duopharma Biotech Shares Rise After Securing RM52.54 Million Government Contract
KUALA LUMPUR, Feb 19, 2026 — Shares of Duopharma Biotech Bhd climbed higher in early trading Thursday after its unit secured a government contract valued at RM52.54 million to supply medical products.
At around 9:49 a.m. MYT, the company’s stock was up seven sen at RM1.55, with roughly 1.38 million shares traded.
In an official filing with Bursa Malaysia, the pharmaceutical manufacturer said its wholly owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), accepted a letter of award (LOA) to supply insulin injections to facilities under the Ministry of Health (MOH). The contract is expected to run until February 5, 2028.
According to the company, the terms of the LOA will be formalised later through a formal agreement between the government and DMSB. Until that agreement is signed, the LOA remains binding on both parties.
Market watchers see the news as positive for Duopharma’s near-term outlook. RHB Investment Bank Bhd said in a note that the acceptance of the LOA should help support the company’s prospects. It highlighted that Duopharma already has an additional LOA from the MOH to supply pharmaceutical products under the Approved Products Purchase List (APPL) contract, which adds further revenue visibility.
RHB also pointed to potential profitability benefits from the recent normalisation of active pharmaceutical ingredient prices and a weaker US dollar, which could improve earnings. Based on its analysis, the investment bank maintained a “buy” call on Duopharma shares with a target price of RM1.65 per share.
Industry reports also show that Duopharma has secured multiple MOH contracts in recent days, including another award worth RM65.08 million for the supply of recombinant human insulin formulations, bringing the total value of new insulin-related contracts to around RM117.6 million. Analysts view these deals as helping to strengthen Duopharma’s earnings pipeline through FY2028
